Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

CONCLUSIONS: After switching to mepolizumab, almost all patients with uncontrolled severe eosinophilic asthma on omalizumab achieved a beneficial response in ≥ 1 clinical outcome. Improvements were observed regardless of baseline characteristics. Trial registration This manuscript is a post hoc analysis of data from the OSMO study. ClinicalTrials.gov, NCT02654145. Registered January 13, 2016.PMID:33971856 | PMC:PMC8111733 | DOI:10.1186/s12931-021-01733-9

Source: Respiratory Care - May 11, 2021 Category: Respiratory Medicine Authors: Mark C Liu Bradley Chipps Xavier Munoz Gilles Devouassoux Miguel Bergna Steven G Smith Robert G Price Dmitry V Galkin Jay Azmi Dalal Mouneimne Frank C Albers Kenneth R Chapman Source Type: research